Evidence map›Paper›PMID 34814849›Full record

ArticleBMC infectious diseases2021

Spectrum of antibiotic resistance in UTI caused by Escherichia coli among HIV-infected patients in Uganda: a cross-sectional study.

George Abongomera, Maurice Koller, Joseph Musaazi, Mohammed Lamorde, Marisa Kaelin, Hannington B Tasimwa, Nadia Eberhard, Jan Hongler, Sabine Haller, Andrew Kambugu and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Molecular characterization of ESBL-producingFrontiers in cellular and infection microbiology · 2026
    Article
  7. Article
  8. The role of uropathogenicJournal of medicine and life · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

George Abongomera *Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, CH 8001, Zurich, Switzerland. george.abongomera@uzh.ch.ORCID http://orcid.org/0000-0001-8794-3674
Maurice Koller *Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, CH 8001, Zurich, Switzerland.
Joseph MusaaziMakerere University Infectious Diseases Institute, Kampala, Uganda.
Mohammed LamordeMakerere University Infectious Diseases Institute, Kampala, Uganda.
Marisa KaelinUniversity Hospital Zurich, Infectious Diseases and Hospital Epidemiology, Zürich, Switzerland.
Hannington B Tasimwa *Makerere University Infectious Diseases Institute, Kampala, Uganda.
Nadia EberhardUniversity Hospital Zurich, Infectious Diseases and Hospital Epidemiology, Zürich, Switzerland.
Jan HonglerDepartment of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, CH 8001, Zurich, Switzerland.
Sabine HallerDepartment of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, CH 8001, Zurich, Switzerland.
Andrew KambuguMakerere University Infectious Diseases Institute, Kampala, Uganda.
Barbara Castelnuovo *Makerere University Infectious Diseases Institute, Kampala, Uganda.
Jan Fehr *Epidemiology, Biostatistics and Prevention Institute, University of Zurich and University Hospital Zurich, Infectious Diseases and Hospital Epidemiology, Zürich, Switzerland.
Infectious Diseases Institute · UGUniversity of Zurich · CHUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntimicrobial drug resistance is one of the top ten threats to global health according to the World Health Organization. Urinary tract infections (UTIs) are among the most common bacterial infections and main reason for antibiotic prescription. The incidence of UTIs appears to be high among people living with HIV. We sought to determine the most common UTI pathogens among HIV infected patients and evaluate their susceptibility towards antibiotics.

methodsWe performed a cross-sectional study among HIV-infected patients aged ≥ 18 years presenting at an HIV care specialized clinic with symptoms suggestive of a urethritis. Urine cultures were subjected to antibiotic susceptibility testing according to Clinical Laboratory Standards Institute. The data was analyzed using STATA, we performed Pearson's Chi-square and Fisher's exact tests to compare differences between proportions.

resultsOut of the 200 patients, 123 (62%) were female. The median age was 41.9 years (IQR 34.7-49.3). Only 32 (16%) urine cultures showed bacterial growth. Escherichia coli was the most commonly isolated uropathogen (72%), followed by Klebsiella pneumoniae (9%). E. coli was completely resistant to cotrimoxazole and ampicillin; resistance to ciprofloxacin and ceftriaxone was 44% and 35% respectively; 9% to gentamicin; no resistance detected to nitrofurantoin and imipenem.

conclusionsOur findings are congruent with the Uganda national clinical guidelines which recommends nitrofurantoin as the first line antibiotic for uncomplicated UTI. Significant ciprofloxacin and ceftriaxone resistance was detected. In the era of emerging antibiotic resistance, understanding the local susceptibilities among sub-populations such as HIV infected patients is crucial. Further investigation is needed to address reasons for the low bacterial growth rate observed in the urine cultures.

Indexed as

Escherichia coli InfectionsHIV InfectionsUrinary Tract InfectionsAdultAnti-Bacterial AgentsCross-Sectional StudiesDrug Resistance, BacterialDrug Resistance, MicrobialEscherichia coliFemaleHumansMicrobial Sensitivity TestsUgandaAnti-Bacterial AgentsAntimicrobial resistanceHIVSub-Saharan AfricaUgandaUrinary tract infections

Identifiers

PMID34814849
PMCPMC8609806
OpenAlexW3217423836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.